International Journal of Hematology

, Volume 103, Issue 2, pp 119–121 | Cite as

Guest editorial: Human mesenchymal stromal/stem cell (MSC)

  • Yasuo MiuraEmail author
Progress in Hematology Mesenchymal Stromal/Stem Cells

About 50 years ago, cells that have the ability to organize bone and marrow tissues in vivo were identified within the physiological bone marrow [1]. Investigators extended these observations and clarified the existence of precursor cells that show a fibroblast-like shape, a colony-forming potency, and a capability to differentiate into osteoblasts, adipocytes, and chondrocytes [2]. Later, these cells were called mesenchymal stem cells [3], and the characteristics of these cells in human bone marrow were analyzed in detail [4]. The important clinical event that attracted the attention of hematologists to mesenchymal stem cells was the striking improvement in serious acute graft-versus-host disease (GVHD) upon intravenous infusion of these cells [5, 6]. Currently, human bone marrow-derived mesenchymal stem cells are prepared as a cell product, which was approved for the treatment of acute GVHD in Japan in September 2015.

In this issue, five review articles by Miura, Cho, Miyamura, Matsuzaki, and Gronthos covered the basics of human mesenchymal stromal/stem cells (MSCs), their clinical applications, the present status of these cells, and the developments that are expected in the near future. Miura introduced the biological characteristics of human MSCs and their current clinical applications and potential, especially for hematological disorders [7]. Kim et al. summarized the molecular mechanisms underlying the immunomodulatory effect, one of the most important therapeutic effects, of human MSCs [8], and Miyamura introduced the clinical results of human MSCs for the treatment of acute GVHD [9]. MSCs that are currently prepared for clinical use are isolated by the adhesion method and culture-expanded in vitro. Therefore, these cells are heterogeneous with regard to their various biological characteristics, which may influence the outcomes of therapy using MSCs. Mabuchi et al. demonstrated the highly efficient purification of the stem cell population of human MSCs using unique surface marker expression profiles [10]. This prospective isolation strategy implies the development of MSC-based cell therapy in the future. Nguyen et al. summarized the interactions between Eph cell surface tyrosine kinase receptors and their ephrin ligands, which mediate hematopoiesis-associated cross-talk between MSCs and hematopoietic cells [11]. Stromal cells that show similar characteristics as MSCs contribute to hematopoiesis through an interaction with hematopoietic stem and progenitor cells in the bone marrow microenvironment [12], and an abnormality in MSC-derived osteoprogenitor cells causes pathological hematopoiesis [13]. Not only are isolated and/or culture-expanded human MSCs a source for cell therapy, but endogenous MSCs could be a therapeutic target in some hematological conditions.

The allogeneic cell product of human MSCs is expected to be available at the bedside in the near future (Fig. 1). This series of progress in hematology review articles will help us to understand the biological characteristics of human MSCs, provide patients with appropriate MSC therapy, and develop novel and innovative MSC-based therapies.
Fig. 1

Major events in the history of MSCs. aGVHD acute graft-versus-host disease, ASH The American Society of Hematology, EBMT The European Group for Blood and Marrow Transplantation, JSHCT The Japan Society for Hematopoietic Cell Transplantation, MSC mesenchymal stromal/stem cell, P 1 phase 1, P 1/2 phase 1/2, P 2 phase 2, P 2/3 phase 2/3



The author thanks Prof. Taira Meakawa for his valuable comments on this series of progress in hematology review articles.


  1. 1.
    Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6:230–47.CrossRefPubMedGoogle Scholar
  2. 2.
    Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;284:143–7.Google Scholar
  3. 3.
    Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.CrossRefPubMedGoogle Scholar
  6. 6.
    Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.CrossRefPubMedGoogle Scholar
  7. 7.
    Miura Y. Human bone marrow mesenchymal stromal/stem cells: current clinical applications and potential for hematology. Int J Hematol. 2015. doi: 10.1007/s12185-015-1920-z.Google Scholar
  8. 8.
    Kim N, Cho SG. Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications. Int J Hematol. 2015. doi: 10.1007/s12185-015-1918-6.Google Scholar
  9. 9.
    Miyamura K. Human mesenchymal stem cell for acute GVHD: need of long term follow up for some remaining concerns. Int J Hematol. 2015 (in press).Google Scholar
  10. 10.
    Mabuchi Y, Matsuzaki Y. Prospective isolation of resident adult human mesenchymal stem cell population from multiple organs. Int J Hematol. 2015. doi: 10.1007/s12185-015-1921-y.Google Scholar
  11. 11.
    Nguyen TM, Arthur A, Gronthos S. The role of Eph/ephrin molecules in stromal–hematopoietic interactions. Int J Hematol. 2015. doi: 10.1007/s12185-015-1886-x.PubMedGoogle Scholar
  12. 12.
    Omatsu Y, Sugiyama T, Kohara H, Kondoh G, Fujii N, Kohno K, et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity. 2010;33:387–99.CrossRefPubMedGoogle Scholar
  13. 13.
    Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464:852–7.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2015

Authors and Affiliations

  1. 1.Department of Transfusion Medicine and Cell TherapyKyoto University HospitalKyotoJapan

Personalised recommendations